Julian Harrison
Stock Analyst at BTIG
(2.08)
# 2,827
Out of 4,944 analysts
38
Total ratings
43.75%
Success rate
-4.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Maintains: Buy | $24 → $25 | $12.51 | +99.84% | 2 | Jun 27, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $8.97 | +345.93% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $11.50 | +265.22% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $13.89 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $20.15 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $1.97 | +356.85% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $1.70 | +370.59% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $0.34 | +2,225.58% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $18.29 | +233.52% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $6.39 | +134.74% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $25 | $24.98 | +0.08% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $56.16 | -9.18% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $68.80 | -37.50% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $16.83 | +137.67% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $37.50 | +14.67% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $3.27 | +22.51% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $1.43 | +10,389.51% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $55.49 | -35.12% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $308.87 | - | 2 | Feb 11, 2022 |
Theravance Biopharma
Jun 27, 2025
Maintains: Buy
Price Target: $24 → $25
Current: $12.51
Upside: +99.84%
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $8.97
Upside: +345.93%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $11.50
Upside: +265.22%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $13.89
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $20.15
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.97
Upside: +356.85%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $1.70
Upside: +370.59%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.34
Upside: +2,225.58%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $18.29
Upside: +233.52%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $6.39
Upside: +134.74%
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $24.98
Upside: +0.08%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $56.16
Upside: -9.18%
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $68.80
Upside: -37.50%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $16.83
Upside: +137.67%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $37.50
Upside: +14.67%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $3.27
Upside: +22.51%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $1.43
Upside: +10,389.51%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $55.49
Upside: -35.12%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $308.87
Upside: -